Research programme: sustained-release siRNA and microRNA therapeutics - Celsion

Drug Profile

Research programme: sustained-release siRNA and microRNA therapeutics - Celsion

Alternative Names: EGEN-002; GEN 2; Research programme: sustained-release siRNA anticancer therapeutics - Celsion

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EGEN; SurModics
  • Developer Celsion Corporation
  • Class MicroRNAs; Small interfering RNA
  • Mechanism of Action MIRN145-microRNA-inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension
  • No development reported Lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Lung-cancer in USA (IV)
  • 01 Mar 2016 Celsion receives patent allowance for TheraSilence™ lung-specific delivery system in USA
  • 12 Mar 2015 Celsion has patent protection for TheraSilenceTM technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top